| Bioactivity | L755507 is a potent, selective agonist of β3-AR with an IC50 of 35 nM. L755507 enhances the homology-directed repair (HDR)-mediated genome editing in CRISPR/Cas9 nickase system[1][2][3]. | ||||||||||||
| Target | IC50: 35 nM (β3-AR) | ||||||||||||
| Invitro | L755507 causes a robust concentration-dependent increase in cAMP accumulation (pEC50 values of 8.5 and 12.3, respectively). Maximal cAMP accumulation with zinterol and L755507 is increased after pretreatment with pertussis toxin. In contrast to cAMP, zinterol, L755507 and L748337 increase phosphorylation of extracellular signal-regulated kinase 1/2 (Erk1/2) with very high potency (pEC50 values of 10.9, 11.7 and 11.6)[1]. L755507 and Scr7 do not reduce cell viability significantly. Scr7 does not affect cell cycle distribution in a range of 10 to 200 μM. L755507 significantly decreases the proportion of cells in the G2/M phase at 10 μM or 40 μM and increases the S-phase cells at 10 μM compare with the DMSO-treated cells[2]. | ||||||||||||
| Name | L755507 | ||||||||||||
| CAS | 159182-43-1 | ||||||||||||
| Formula | C30H40N4O6S | ||||||||||||
| Molar Mass | 584.73 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Sato M, et al. The beta3-adrenoceptor agonist 4-[[(Hexylamino)carbonyl]amino]-N-[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]-phenyl]-benzenesulfonamide (L755507) and antagonist (S)-N-[4-[2-[[3-[3-(acetamidomethyl)phenoxy]-2-hydroxypropyl [2]. Guoling Li, et al. Small molecules enhance CRISPR/Cas9-mediated homology-directed genome editing in primary cells. Sci Rep. 2017; 7: 8943. [3]. Murakami Y, et al. An effective double gene knock-in strategy using small-molecule L755507 in the medaka fish (Oryzias latipes). Genesis. 2022;60(1-2):e23465. |